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ABSTRACT 
Protein fatty acylation is included in the class of modifications where attachment 
via an acyl linkage is employed including myristoylation and palmitoylation. This work 
focuses on applying the novel tetrazine moiety to covalently target alkene functionalized 
fatty acids via a highly sensitive and selective inverse electron demand Diels alder cyclo-
addition (iEDDA) reaction with accompanied visualization via in gel fluorescence 
imaging or western blot analysis. 
This strategy was used in this study to compare the incorporation of the terminal 
alkene versus alkyne fatty acids mimics, by labeling of the modified proteins via iEDDA 
and Copper assisted Azide-Alkyne Cycloadditon (CuAAC), respectively. The successful 
labeling of the incorporated terminal alkene fatty acid provides another strategy for 
investigating fatty acyl modifications and so assist in validating the established library of 
curated fatty acyl modifications. Additionally, while differences in the location and 
intensity of labeling was observed between the alkene and alkyne fatty acid surrogates 
utilized in this study it was impossible to formulate conclusions on the effectiveness of the 
iEDDA labeling method over the traditionally used CuAAC strategies without 
quantitative mass spectroscopy data.  
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INTRODUCTION  
 
 
Post translational modifications (PTM) include the array of chemical and 
enzymatic alterations to amino acid residues which augment the chemical diversity of 
proteins[1]. These alterations can range from the attachment of simple functional groups 
to the addition of small molecules and macromolecules. Protein fatty-acylation describes 
one such modification; it involves the covalent attachment of assorted fatty acids onto 
the amino acid side chain residues of cysteine, serine, threonine, NƐ-lysine and N-
terminal amines. These transformations have been shown to affect the subcellular 
localization and activity of protein-protein and protein-membrane interactions in a wide 
variety of biological processes and associated disease states[2].  
In one example, the palmitoylation (16-carbon fatty acid modification) of Wnt 
proteins was identified as essential for its proper functioning as it increased the ….with 
defective Wnt signaling implicated in several forms of cancer and degenerative 
diseases[3]. Similarly, myristoylation (14-carbon fatty acid modification) of structural 
proteins on HIV-1 (Human Immunodeficiency Virus 1) has been shown to affect its viral 
infectivity [4]. These examples illustrate the key role that protein fatty acylation play in 
cellular homeostasis and underscore the importance of determining their amenability to 
serve as either disease biomarkers, for diagnostic applications, or as therapeutic targets 
for pharmacological applications. 
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Dietary fats are obtained from a variety of sources and consist mostly of long 
chain fatty acids. These are highly condensed energy sources, contributing 
approximately 30-40% of an individual’s daily energy intake.  Those with chain lengths 
more than three carbons are enzymatically converted into fatty acyl-CoAs by their 
corresponding acyl-CoA synthetases [5]. These undergo repeated cycles of β-oxidation to 
produce acetyl-CoA that enters into the tricarboxylic acid cycle (TCA), eventually 
yielding intracellular energy carrier molecules such as adenosine triphosphate (ATP). 
The variety of acyl-Co-A intermediates formed over the course of β-oxidation are high-
energy labile thioesters well suited to participate in nucleophilic acyl substitution 
reactions with protein nucleophiles.( Figure 1) 
 
 
Figure 1: A diagrammatic summary of the mechanism of fatty acylation. Nu: represents the amino acid side chain functional groups of serine, cysteine and NԐ-lysine as well as glycine free amine. R represents the variety of fatty acid chain lengths observed on acyl-Co-A intermediates formed via the β-oxidation pathway.  
The challenges of studying fatty acid modifications has been well 
documented[6],[7]. The lack of specific antibodies for fatty acid modifications has resulted 
in initial investigations being limited to the use of radioactively labeled chemical 
reporters, typically [H3 ] or [ I125] containing fatty acids[8]. These often require lengthy 
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exposure times (1-3 months), produce weak signals and in certain cases require high 
financial investment [9]. Furthermore, the difficulties associated with chromatographic 
separation of highly hydrophobic fatty acylated proteins, the poor ionization of samples 
and low sensitivity of mass spectroscopy detection have made these traditional research 
methods almost impractical [7].  
This has prompted a shift towards the use of small molecule techniques. Small 
molecule strategies involve the incorporation of functionalized chemical reporter 
molecules followed by reaction with a complementary capture probe to facilitate the 
visualization or isolation of the pre-targeted cellular components from the complex 
biological milieu [9],[10], [11] . Developments in bio-orthogonal reaction chemistry has 
provided a range of different functionalities as potential fatty acid mimics. For instance, 
chemical reporters with chloroacetyl, terminal alkyne, terminal azide and strained 
alkenes were identified as possible functionalities to serve as selective reporter 
molecules. It was found that the application of a chloroacetyl reporter resulted in high 
cellular toxicity and so could not be used in direct cellular application. The strained 
alkenes on the other hand showed low incorporation and so were not suitable for 
biological applications [12],[13].  
The use of terminal alkyne or azide functionalized fatty acids however has 
proved successful. This example has found the widest application and greatest 
documented success [14]. Once incorporated into the cellular proteome the installed azide 
or alkyne is coupled via the copper assisted azide alkyne cycloaddition (CuAAC) with a 
complementary capture probe. Or in addition terminal azides may also be targeted using 
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phosphines via the Staudinger ligation reaction. The aqueous compatibility and rapid 
reaction kinetics of the azide-alkyne labeling strategy has encouraged their utility in the 
profiling of fatty acylation despite their noted spatial and structural difference from 
native dietary fatty acids[14]. (Figure 2) Note that the azide and alkyne surrogates show a 
clear spatial and structural difference from the native fatty acid particularly in their 
terminal functionalty. The azide and alkyne are significantly longer and less 
hydrophobic than the terminal alkyl group of the myristic acid and shows better 
similarity to the 13-tetradecenoic acid in this respect.   
 
 
         
                     
 
 
 
  Figure 2: A space-filled and line representations of myristic acid and its alkene, alkyne and azide surrogates - 13-tetradecenoic acid, 13-tetradecynoic acid and 12-azidododecanoic acid. [Green – carbon, white- hydrogen, red- oxygen, blue- nitrogen]    
While a large dataset of proteomic profiling studies on fatty acylation 
(palmitoylation) has been curated at SwisPalm ( http://swispalm.epfl.ch/), only a meager 
10% has been validated[7]. In addition a number of false positive results have identified 
within this dataset indicating a need for the development of alternative strategies for not 
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only profiling fatty acyl modifications but also validating the results which has been 
accumulated. Thus, while azides and alkynes may appear to serve as mimics of fatty acid 
substrates their structural differences may in reality result in a non-canonical metabolic 
process leading to partial or improper fatty acylated targets [15]. This necessitates the 
development of alternative strategies to not only validate current data sets of fatty 
acylated modifications but also to offer improved methodologies for profiling of protein 
post translational fatty acid modifications. The similarity of a terminal alkene fatty acid 
mimic both in shape and hydrophobicity to the corresponding native fatty acids 
facilitates their incorporation into the innate fatty acid metabolic pathways and reduces 
the likelihood of off target acylation.  
Furthermore, the use of a terminal olefin reporter molecule facilitates the 
application of a tetrazine capture probe, which provides a selective bio-orthogonal 
conjugation mechanism. Additionally, the probe may be functionalized for rapid 
visualization using a fluorescent moiety or a biotin tag for enrichment and isolation of 
the modified proteome[16].  
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A CHEMICAL-BIOLOGY STRATEGY: TETRAZINE + TERMINAL ALKENE 
 
 
THE FATTY ACID MIMIC 
The similarity in shape and hydrophobicity of the terminal-olefin chemical 
reporter to corresponding native fatty acids suggests that they would serve as successful 
and efficient mimics of native fatty acids. This should allow these small molecules to 
seamlessly be accepted by endogenous enzymes and so provide a better representation of 
fatty acylation activities.  
This study utilized only even numbered long-chain terminal-olefin fatty acids as 
odd numbered acids were not expected to lead to significantly different labeling results. 
The fatty acids, which were used were obtained from two sources; those with 6-10 
carbons were obtained via commercial sources, while those with C12, C14, and C16 
were synthesized in the laboratory (Figure 3).  In order to determine the effectiveness of 
our terminal alkene reporter a similar C14 terminal alkyne fatty acid reporter, was 
prepared (Figure 4). 
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Figure 3: The synthetic strategy to prepare the terminal-olefin fatty acids C12e, C14e, C16e for metabolic labeling. Using the commercially available 11-bromo-1-undecene, via the following steps: a. Magnesium, Iodide, anh. THF; b. CO2; c. DCM, DHP, PTSA, 0oC - r.t.; d. anh. DCM, anh. Pyridine, pTSCl, r.t.; e. anh. THF; f. Li2CuCl4, r.t.; g. Acetic acid, CrO3, H2O, 0oC-r.t.  
 
Figure 4: The synthetic strategy to prepare the terminal- alkyne fatty acid C14y for metabolic labeling. Starting with the commercially available 12-bromo-1-dodecanol according to the following steps: h. Acetic acid, CrO3, H2O, 0oC-r.t.; i. TMS-acetylene, n-BuLi, anh THF, -78 oC-r.t. j. K2CO3, MeOH, r.t.   
 
THE CHEMICAL REPORTER 
In selecting the tetrazine chemical reporter for this study we reflected on the 
results published by Lee et. al. where a benzoic acid substituted tetrazine (35a) reacted 
successfully and with good reaction kinetics to a number of unstrained terminal alkenes. 
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In addition, Lee et. al also showed that a biaryltetrazine (35b) was effective in avoiding 
non-specific labeling of free cysteine side chains on BSA[16]. Furthermore, interest in the 
biaryltetrazine was shown by Pipkorn and coworkers who demonstrated that the 
biaryltetrazine (35b) proved compatible with aqueous solutions containing amines and 
disulfides [17]. Meanwhile Karver et. al. determined that the aqueous solubility of the 
tetrazine was 0.2 mM as a result stock solutions were prepared in DMSO and kinetic 
evaluation of the iEDDA reaction used a maximum concentration of only 5 M of the 
tetrazine dye[18]. 
  
  Figure 5: The chemical structure of the tetrazine molecules studied by Lee et. al.[16]   
As the reaction kinetics for the biaryltetrazine containing a pyrimidyl and 
benzoic acid substituent has not yet been published, tetrazine 33 (Tz-F) was prepared, to 
expedite this process. Furthermore, to achieve the objective of protein enrichment a 
biotin conjugated analog, 32 (Tz-B) was also prepared (Figure 6).  
 
9 
Figure 6: The synthetic scheme for the preparation of chemical reporters 32 [Tz-B] and 33 [Tz-F] used for targeted labeling of fatty acyl modifications. Reagents and conditions: l. NH2NH2.H2O, anh. EtOH, reflux 90oC; m. Acetic acid, NaNO2, H2O, 10 oC; p. anh DMF, HATU, DIPEA, r.t. q. anh MeOH, 4M HCl in 1,4 dioxane, 0 oC-r.t.; r. anh DMF, DIPEA, NHS-Biotin , r.t.; s. anh MeOH/THF 2:1, TEA, FITC, 0 oC-r.t. 
MATERIALS AND METHODS 
General information 
All reactions involving moisture sensitive reagents were performed using oven 
dried glassware under nitrogen atmosphere. Anhydrous solvents were obtained from 
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commercial sources or via distillation using standard laboratory protocols. Analytical 
thin-layer chromatography (TLC) was performed on EMD Millipore silica gel 60 F254 
plates. Visualization was accomplished by UV irradiation at 254 nm or by staining with 
ninhydrin (0.3% w/v in glacial acetic acid/n-butyl alcohol 3:97). Flash column 
chromatography was performed with flash silica gel (particle size 32-63 μm) from 
Dynamic Adsorbents Inc. (Atlanta, GA). Proton NMR spectra were obtained on Varian 
300 and 500 MHz NMR spectrometers. Chemical shifts are reported as δ values in parts 
per million (ppm) as referenced to the residual solvents: deuterated chloroform (7.27 
ppm for 1H and 77.23 ppm for 13C); deuterium oxide (4.80 ppm for 1H); dimethyl 
sulfoxide (2.50 ppm for 1H and 39.51 for 13C). 1H NMR spectra are tabulated as follows: 
chemical shift, (multiplicity; s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet), number of protons).  
 
Synthesis of 12- carbon terminal alkenyl fatty acid [C12e] 
 
  (1) 
 
The dodec-11-enoic acid was prepared in a similar fashion as reported by Wube 
et al.[19]. The halide 1 ( 1 eq, 0.5 mL, 2.0 mmol) was added to a stirring mixture of 
activated magnesium (2.5 eq, 138 mg, 5.1 mmols) and iodide (catalytic) in anhydrous 
tetrahydrofuran under inert atmosphere while gently heating. When the solution was 
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decolorized heating was stopped and carbon dioxide was bubbled through the reaction 
mixture to give a thick creamy mixture. The reaction was quenched by the addition of 
chilled saturated ammonium chloride solution (10 mL) and diluted with diethyl ether (20 
mL). The organic phase was separated and sequentially washed with water (20 mL), 
saturated sodium bicarbonate (20 mL) and saturated sodium chloride (20 mL), dried with 
sodium sulfate and concentrated via rotary evaporation. Purification was achieved via 
silica gel column chromatography eluting with a mixture of hexanes/ ethyl acetate to 
obtain 3 (300 mg, 67%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 5.85 (m, 1H), 
5.05-4.99 (m, 2H), 2.37 (m, 2H), 2.08 (m, 2H), 1.68 (m, 2H), 1.31 (m, 14H). 
      
Synthesis of 14- carbon terminal alkenyl fatty acid [C14e] 
 
      (2) 
 
Propane diol was protected with DHP using the strategy described by Guillod et. 
al. [20].To a solution of propane diol, 3 (2 eq, 5.34 mL, 78.8 mmols) in anhydrous DCM 
(20 ml) was added p-toluene sulfonic acid (0.4 eq, 300 mg, 1.7 mmols) portion-wise. 
The solution was cooled to 0 oC and DHP (1 eq, 3.8 mL, and 41.7 mmols) was added 
dropwise over 2 hours and the mixture warmed to room temperature. The reaction 
mixture was washed with water, dried with anhydrous NaSO4 and purified via silica 
column chromatography eluting with 70:30 hexanes/ethyl acetate. The product, 4 was 
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collected as a colorless oil (2.88 g, 90%) 1H NMR (300Mz, CDCl3) δ 4.61 (s, 1H), 3.85 
(m, 2H), 3.53 (m, 2H), 1.92 -1.54 (m, 8H). 
 
     (3) 
 
The mono protected alcohol was further protected using the method published by 
Guillod et. al. [20]. To the solution of 4, (1 eq, 1.67 g, 10.4 mmols) in anhydrous DCM 
(10 mL) under inert atmosphere conditions was added anhydrous pyridine (2 eq, 1.68 
mL, 20.8 mmols). Toluene sulfonyl chloride (1.25 eq, 2.49 g 15.6 mmols) was dissolved 
in anhydrous DCM (5 mL) and added portion wise at room temperature to give a yellow 
solution. Consumption of alcohol 5 was confirmed via TLC. The reaction mixture was 
then diluted with a portion of DCM (25 mL), sequentially washed with 5% HCl solution 
(2 x 30 mL), saturated NaHCO3 solution ( 2 x 30 mL), saturated NaCl solution ( 2 x 30 
mL),  dried with MgSO4, filtered and concentrated via rotary evaporation. Purification 
was performed via silica gel column chromatography eluting with 70:30 hexanes/ethyl 
acetate to obtain 5 (1.6 g, 49%), as yellow oil. 1H NMR (300Mz, CDCl3) δ 7.81 (d, 2H), 
7.36 (d, 2H), 4.45( s, 1H), 4.14 (m, 4H), 3.81 (m, 2H), 3.45 ( m, 2H), 2.48 (s, 3H), 1.95 
(m, 2H), 1.85-1.48 (m, 8H). 
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                                                                          (4)   The grignard reaction of the protected diol with the alkenyl halide was performed 
as documented by Rezanka and coworkers [21]. A solution of halide 1 ( 1.5 eq, 0.3 mL, 
1.3 mmol) in anhydrous THF (5 mL), was added to a stirring mixture of activated 
magnesium (2.5 eq, 56 mg, 2.3 mmols) and iodide (catalytic) in anhydrous THF( 10 mL) 
under inert atmosphere while gently heating. When the solution was decolorized heating 
was stopped and the protected diol 5 (1 eq, 290 mg, 0.9 mmols) was added dropwise. 
The solution was stirred for 3 hours unheated following which Li2CuCl4 (0.2 eq, 0.2 mL, 
0.18 mmols) was added. The resulting green mixture continued to stir at room 
temperature overnight to yield a yellow brown mixture. This was sequentially extracted 
with chilled NH4+Cl- (20 mL ), water (40 mL), saturated NaHCO3 (20 mL), saturated 
NaCl (20 mL), dried with Na2SO4 and concentrated via rotary evaporation to give a 
mixture of 6 and 7. Purification via silica gel column chromatography elution with 70:30 
hexanes/ethyl acetate isolated 7 (80 mg, 40%) and 6 (196 mg, 72%) as colorless oils. 1H 
NMR (300Mz, CDCl3) δ 5.85 (m, 1H), 5.05-4.94 (m, 2H), 4.61 ( m, 1H), 3.90 (m, 2H), 
3.42 (m, 2H), 2.05 (m, 2H), 1.58 (m, 6H), 1.42-1.32 (m, 16H). 
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      (5) 
 
p- Toluene sulfonic acid (0.05 eq, 60 mg, 0.34 mmols) was added to 6 (1 eq, 196 
mg, 6.6 mmols) dissolved in methanol (10 mL) and stirred overnight at room 
temperature. Sodium hydroxide (1M, 0.5mL) was added and the reaction was 
concentrated. The residue was re-dissolved in ethyl acetate and sequentially washed with 
water (10 mL), saturated NaHCO3 solution (10 mL), saturated NaCl solution (10 mL), 
dried with sodium sulfate and concentrated. The crude oil was purified via silica gel 
column chromatography 90:10 hexane/ ethyl acetate to give 7 (115 mg, 85%), as a 
colorless oil. 1H NMR (300Mz, CDCl3) δ 5.85 (m, 1H), 5.05-4.94 (m, 2H), 3.67 (t, 2H), 
2.37 (t, 1H), 2.05 (m, 2H), 1.59 (m, 4H), 1.42-1.32 (m, 16H). 
 
       (6) 
 
Acetic acid (2.1 mL) was added to an ice cold solution of CrO3 (3.9 eq, 201 mg, 
3.1 mmols) in water (1 mL) to prepare the Jones’ reagent. The alcohol 7 (1 eq, 110 mg, 
0.52 mmols) was dissolved in acetone (0.5 mL) and cooled to 0oC before being added 
drop wise to the Jones’ solution maintained at 0oC. Following complete addition of the 
alcohol the mixture was allowed to warm to room temperature and continuously stirred 
overnight.  The dark solution was diluted with water and the pH was adjusted to ~8-10.  
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This was extracted with diethyl ether (20 mL) and the aqueous phase was separated. The 
aqueous phase was pH adjusted to ~4-6 and extracted with ethyl acetate (20 mL). The 
ethyl acetate phase was dried with Na2SO4 and concentrated to yield the alkenyl acid 8 
(99.5 mg, 85%), as a colorless oil. 1H NMR (300Mz, CDCl3) δ 5.85 (m, 1H), 5.05-4.94 
(m, 2H), 3.67 (m, 2H), 2.05 (m, 2H), 1.65 (m, 2H), 1.37 (m, 16H). 
 
Synthesis of 16- carbon terminal alkenyl fatty acid [C16e] 
 
     (7) 
 
Pentane diol was protected with DHP using the strategy described earlier [20].To 
solution of 9 (1.5 eq, 6 mL, 57.6 mmols) in anhydrous dichloromethane (20 ml) was 
added p-toluene sulfonic acid (0.08 eq, 550 mg, 3.2 mmols) portion-wise. The solution 
was cooled to 0 oC and dihydropyran (1 eq, 2.7 mL, and 38.4 mmols) was added 
dropwise over 2 hours as the mixture warmed to room temperature. The reaction mixture 
was washed with water, dried with anhydrous sodium sulfate and purified via silica 
column chromatography eluting with 70:30 hexanes/ ethyl acetate. The product, 10 was 
collected as a colorless oil (5.3 g, 73%) 1H NMR (300Mz, CDCl3) δ 4.59 (s, 1H), 3.85-
3.36 (m, 6H), 1.86-1.41 (m, 14H). 
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      (8) 
 
A solution of 10, (1 eq, 5.3 g, 28.2 mmols) in anhydrous DCM (10 mL) under 
inert atmosphere conditions was chilled and triethylamine (3 eq, 12.2 mL, 84.6 mmols) 
was added dropwise. The solution was stirred for 10 min and a chilled solution of p-
toluene-sulfonyl chloride (1 eq, 5.4 g, 28.2 mmols) in anhydrous DCM (5 mL) was 
added portion wise. The reaction was allowed to continue overnight warming to room 
temperature.  A portion of DCM (25 mL) was used to dilute the reaction mixture and the 
reaction was quenched with 5% HCl solution (50 mL). The organic phase was washed 
with saturated NaHCO3 solution (30 mL), saturated NaCl solution (30 mL), dried with 
MgSO4, filtered and concentrated via rotary evaporation. Purification was performed via 
silica gel column chromatography eluting with 80:20 hexanes/ ethyl acetate to obtain 11 
(6.0 g, 62%) as a colorless oil. 1H NMR (300Mz, CDCl3) δ 7.80-7.33 (d, 2H), 7.36 (d, 
2H), 4.57-4.54 (m, 1H), 4.55-4.03 (m, 1H) 3.80-3.73 (m, 2H), 3.53-3.37 (m, 2H), 2.47 
(s, 3H), 1.86-1.52 (m, 14H). 
 
       (9) 
 
The grignard reaction of the protected pentane diol with the alkenyl halide was 
performed as detailed earlier [21]. A solution of halide 1 ( 1 eq, 2 mL, 9.1 mmol) in 
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anhydrous THF (5 mL), was added to a stirring mixture of activated magnesium (5 eq, 
1.1 g, 45.3 mmols) and iodide (catalytic) in anhydrous THF( 10 mL) under inert 
atmosphere while gently heating to reflux. When the solution was decolorized heating 
was continued for 3 hrs following which the mixture was allowed to cool slightly before 
the protected diol 11 (1 eq, 3 g, 9.5 mmols) dissolved in THF was added dropwise. Once 
the addition was completed the reaction mixture was stirred for another hour and 
Li2CuCl4 (0.2 eq, 0.2 mL, 0.18 mmols) was added. The resulting greenish mixture was 
allowed to stir at room temperature overnight to yield a yellowish mixture. This was 
washed with chilled NH4+Cl- (20 mL), water, saturated NaHCO3, saturated NaCl, dried 
with Na2SO4 and concentrated via rotary evaporation to give 13. Purification was 
completed via silica gel column chromatography elution with 90:10 hexanes/ ethyl 
acetate to yield 13 (440 mg, 15%) as a colorless oil. 1H NMR (300Mz, CDCl3) δ 5.85 
(m, 1H), 4.97 (m, 2H), 3.67 (m, 2H), 2.07 (m, 2H), 1.57 (m, 4H), 1.31 (m, 18H). 
 
       (10) 
 
Acetic acid (3.1 mL) was added to an ice cold solution of CrO3 (3.9 eq, 308 mg, 
3.1 mmols) in water (1 mL) to prepare the Jones’ reagent. The alcohol 13 (1 eq, 190 mg, 
0.80 mmols) was dissolved in acetone (0.8 mL) and cooled to 0oC before being added 
dropwise to the Jones’ solution. The reaction mixture was allowed to warm to room 
temperature, while continuously stirring overnight.  The dark solution was diluted with 
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water and the pH was adjusted to ~8-10.  This was extracted with diethyl ether (30 mL) 
and the aqueous phase was separated. The aqueous phase was pH adjusted to ~4-6 and 
extracted with ethyl acetate (30 mL). The organic layer was dried with Na2SO4 and 
concentrated to yield the alkenyl acid 14 (180 mg, 89%), as a colorless oil.  
1H NMR (300Mz, CDCl3) δ 5.73 (m, 1H), 4.87 (m, 2H), 2.28 (m, 2H), 1.95 (m, 2H), 
1.56 (m, 2H), 1.31 (m, 20H). 
 
Synthesis of 14 carbon terminal alkynl fatty acid [C14y] 
 
       (11) 
 
The bromo acid was prepared as described by Wube et. al, acetic acid (13.1 mL) 
was added to an ice cold solution of CrO3 (3.9 eq, 1.47 g, 18.5 mmols) in water (3 mL) 
to prepare the Jones’ reagent, a yellow-orange solution[19]. The alcohol 15 (1 eq, 1.0 g, 
3.8 mmols) was dissolved in acetone (3.75 mL) and cooled to 0oC before being added 
dropwise to the Jones’ solution. The reaction mixture was maintained at 0oC for 2 hours 
before being allowed to warm to room temperature, while continuously stirring.  The 
dark solution was diluted with water and the pH was adjusted to ~8-10.  This was 
extracted with diethyl ether (20 mL) and the aqueous phase was separated. The aqueous 
phase was pH adjusted to ~4-6 and extracted with ethyl acetate (30 mL). The organic 
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layer was dried with Na2SO4 and concentrated to yield the alkenyl acid 14 (806 mg, 
82%), as a colorless oil. 1H NMR (300Mz, CDCl3) δ 10.6 (br, 1H), 4.15 (m, 2H), 3.44 
(m, 2H), 2.38 (m, 2H), 2.05 (m, 2H), 1.84 (m, 2H), 1.64 (m, 2H), 1.43 (m, 2H), 1.29 (m, 
8H). 
 
      (12) 
 
To a solution of TMS acetylene (2.5 eq, 0.64 mL, 4.5 mmols) in anhydrous THF 
(5mL) at -78oC under inert atmosphere was slowly added n-butyl lithium [1.6M/ 
Hexanes] (3 eq, 3.36 mL, 5.37 mmols)[19, 22]. The reaction mixture was removed from 
the dry ice bath and allowed to stir for 2 mins as a solution of 16 (1 eq, 500 mg, 1.79 
mmol) in anhydrous THF (2.5 mL) was prepared. The reaction mixture was returned to 
the dry ice bath and the solution of 16 was added followed by HMPA (20 eq, 6.2 mL, 
35.8 mmols) dropwise. The creamy beige mixture was stirred at -78oC warming to room 
temperature to produce first a bronze-brown mixture continuing to darken to a dark 
brown almost black appearance at room temperature. This was allowed to stir overnight. 
The reaction mixture was again cooled to -78oC and quenched by the addition of chilled 
saturated NH4Cl solution. This mixture was extracted with DCM (3 x 20 mL) and the 
combined organic layers was washed with saturated NaCl solution (3 x 20 mL), dried 
with MgSO4 and concentrated by rotary evaporation. The crude product was purified via 
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silica gel column chromatography eluting with 70:30 hexanes/ ethyl acetate to yield 17 
(112 mg, 21%). 1H NMR (300Mz, CDCl3) δ 2.17 (m, 2H), 2.06 (m 2H), 1.96 (m, 4H), 
1.36 (m, 4H), 1.12 (m, 10H), 0.01 (m, 9H). 
 
      (13) 
 
To a solution of 17 (1 eq, 112 mg, 0.38 mmols) in MeOH (5mL) was added 
K2CO3 (0.15 eq, 8.2 mg, 0.06 mmols) and the reaction mixture was allowed to stir 
overnight at room temperature [19, 22]. It was then concentrated by rotary evaporation and 
the residue was diluted with ethyl acetate. The mixture was then extracted with 5% HCl 
solution, dried with Na2SO4 and concentrated to yield a colorless oil 18 ( 85.5 mg, 67%). 
1H NMR (300Mz, CDCl3) δ 2.21 (m, 2H), 2.04 (m, 2H), 1.79 (s, 1H), 1.48 (m, 2H), 1.37 
(m, 2H), 1.20-1.12 (m, 14H). 
 
Synthesis of the tetrazine chemical reporters Tz-B and Tz-F   
H2N NH2 H2N NHBocn 2019       (14)  
 
A solution of diamine 19 (5 eq, 32 mL, 0.48 mols) was prepared in 1,4 dioxane 
(100 mL) in a large round bottomed flask. A solution of di-tertbutyl dicarbonate (1 eq, 
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12.8 g, 0.06 mols) was also prepared in 1,4 dioxane ( 100 mL) and added to a pressure 
equalized graduated addition funnel. The di-tertbutyl dicarbonate solution was added to 
the diamine solution dropwise at room temperature and allowed to continue overnight as 
the initially colorless solution slowly became cloudy. The solvent was evaporated via 
high vacuum and the residue was resuspended in water (250 mL) the insoluble material 
was removed via vacuum filtration and the aqueous solution was extracted with DCM (3 
x 150 mL). This was concentrated to give 20 (8 g, 69%) as a clear oil. 1H NMR (300Mz, 
CDCl3) δ 4.93 (s, 1H), 3.67 (m, 2H), 3.21 (m, 2H), 2.75 (m, 2H), 1.62 (m, 2H), 1.46 (s, 
9H). 
 
NHO H
HN
H S
O
O N O
ONHO H
HN
H S
O
OH
30 31
t
   (15) 
 
Using the method described by Kang et. al., N-Hydroxysuccinimide (1.1 eq, 
0.371 g, 3.2 mmols) was added to a solution of 30 (1 eq, 1.0 g, 2.93 mmols) in DMF 
cooled to 0 oC. N,N-Dicyclohexylcarbodiimide (1.3 eq, 0.786 g, 3.8 mmols) was added 
all at once and the reaction mixture was allowed to stir and warm to room temperature 
overnight [23]. The pale yellow mixture was filtered to remove any unreacted 22, and the 
filtrate was concentrated to give 31 (0.873 g, 87%) as a cream-white solid. 1H NMR 
(300Mz, DMSO) δ 6.43 (d, 2H), 4.31 (m, 1H), 4.16 (m, 1H), 2.87 (m, 2H), 2.82 (m, 4H), 
2.68 (m, 2H), 1.63 (m, 3H), 1.46 (m, 3H). 
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   (16) 
 
The tetrazine (25) was prepared as described by Chen and coworkers [16], [18], [24], 
[25] . To a mixture of 23 (1.5 eq, 1.96 g, 14.3 mmols) and 24 (1 eq, 0.935 g, 9.5 mmols) in 
dried ethanol (30 mL) was added hydrazine monohydrate (18 eq, 5.5 mL, 0.18 mols) 
dropwise, under inert atmosphere at room temperature. The initially grey mixture slowly 
changed to yellow, then burgundy as the mixture was heated to 90oC and allowed to 
reflux overnight. The mixture was allowed to cool and the crude product was obtained 
by filtering the thick mixture and washing with acetone (10 mL). The yellowish solid 
which resulted was placed in an erlenmeyer flask and chilled in an ice bath. Cold acetic 
acid (10 mL) was added to the crude product followed by a cold aqueous solution of 
NaNO2 (2.76 g/ 10 mL H2O). The reaction mixture changed to a bright pink-purple color 
and dark brown gas was observed. This mixture was allowed to stir in the ice bath for 
15-20 min until no more brown gases were observed. The mixture was diluted with 
DCM (2 x 50 mL) and concentrated for purification.  The product 25 was purified via 
silica gel column chromatography eluting with 95:5 hexane/ ethyl acetate to obtain the 
product (200 mg, 8%). 1H NMR (300Mz, DMSO) δ 9.21 (d, 2H), 8.71 (d, 2H), 8.25 (d, 
2H), 7.83 (m, 1H). 
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  (17) 
 
The tetrazine (26) was prepared as described by Chen and coworkers [16],  [24].  To 
a solution of tetrazine 25 (1 eq, 100 mg, 0.36 mmols) and diisopropylethylamine 
[DIPEA] (2.5 eq, 0.233 mL, 1.34 mmols) in anhydrous DMF (10mL) was added HATU 
(1.5 eq, 203 mg, 0.54 mmols). This was allowed to stir at room temperature under inert 
atmosphere for 1 hour before addition of the protected amine 21 (1.5 eq, 86 mg, 0.54 
mmols) following which the reaction mixture was allowed to stir overnight. It was then 
diluted with ethyl acetate (20 mL) and washed with water (3 x 20 mL), saturated sodium 
chloride solution (20 mL), dried over anhydrous sodium sulfate and concentrated via 
rotary evaporation. The crude product was purified via silica gel column 
chromatography eluting with 2-10% MeOH: DCM to afford the tetrazine 26, (124 mg, 
82%) as a purple solid. 1H NMR (300 Mz, DMSO) δ 9.24 (m, 2H), 8.71 (m, 2H), 8.16 
(m, 2H), 7.86 (m, 1H), 6.85 (m, 1H), 3.03 (m, 2H), 1.69 (m, 2H), 1.39 (s, 9H). 
 
 
 (18)  Tetrazine 28 was prepared in a similar fashion as tetrazine 25 (1 eq, 128 mg, 0.45 
mmols), DIPEA (2.5 eq, 0.199 mL, 1.14 mmols), HATU (1.5 eq, 261 mg, 0.69 mmols) 
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and protected amine 20 (1.5 eq, 119 mg, 0.69 mmols). After silica gel column 
chromatography the tetrazine 28 (119 mg, 80%) was obtained also as a purple solid. 1H 
NMR (300Mz, CDCl3) δ 9.17 (d, 2H), 8.86 (d, 2H), 8.19 (d, 2H), 7.66 (d, 1H), 4.92 (s, 
1H), 3.62 (m, 2H), 3.30 (m, 2H), 1.81 (m, 2H), 1.49 (s, 9H). 
 
 (19) 
 
 Boc-deprotection of tetrazine 26 and 28 was achieved using the methodology 
described by Lang et. al.[26]. The tetrazine 26 (1 eq, 124 mg, 0.29 mmols) or 28 (1 eq, 40 
mg, 0.09 mmols) was dissolved in dry MeOH (~6ml or ~2 mL respectively) and chilled 
to 0oC. To this was added 4M HCl in dioxane (4 eq, 0.29 mL, 1.17 mmols) or (30 eq, 
0.69 mL, 2.75 mmols) slowly. The reaction mixture was allowed to warm to room 
temperature stirring for ~1 hr following this the solvent was removed via rotary 
evaporation. The residue collected was suspended in diethyl ether and decanted to 
collect a purple solid. This was repeated and the deprotected tetrazine was collected via 
filtration as a purple salts, 27 (55 mg, 52%) and 29 (29 mg, 96%).  
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   (20) 
 
 
The tetrazine 29 (1 eq, 50 mg, 0.14 mmols) was dissolved in a minimum of dry 
DMF and DIPEA (7.6 eq, 138 µL, 1.07 mmols). The reaction mixture was stirred for 5 
min before the biotin N-hydroxysuccinimide ester was added (1.3 eq, 61.8 mg, 0.18 
mmols) was added. The reaction was allowed to warm to room temperature stirring 
overnight to yield an orange solution. The reaction mixture was concentrated and 
purified via silica gel column chromatography eluting with a mixture of DCM- MeOH 
(100:0 to 80:20) to obtain the purified tetrazine-biotin conjugate. 32 (17 mg, 33%) 1H 
NMR (300Mz, DMSO) δ 9.17 (m, 2H), 8.79 (d, 2H), 8.12 (d, 2H), 7.79 (m, 2H), 7.19 
(m, 1H), 6.85 (m, 2H), 6.55 (m, 4H), 3.80 (m, 2H), 3.50 (m, 4H), 2.10 (m, 2H), 1.38 (m, 
2H). 
 
  (21) 
 
The pink solution of tetrazine 27 (1 eq, 29 mg, 0.09 mmols) dissolved in a 2:1 
mixture of dry MeOH and THF (3 mL) changed to purple upon addition of TEA (10 eq, 
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66 µL, 0.91 mmols). The reaction mixture was cooled to 0 oC before fluorescein 5-
isothiocyanate (FITC) (1.3 eq, 28 mg, 0.07 mmols) was added. The reaction was allowed 
to warm to room temperature stirring overnight to yield an orange solution. The reaction 
mixture was concentrated and purified via silica gel column chromatography eluting 
with a mixture of DCM: Acetone: MeOH (80:10:10 to 0:90:10) to obtain the purified 
tetrazine-fluorescein conjugate, 33 (17 mg, 33%). 1H NMR (300Mz, MeOD) δ 9.19 (s, 
2H), 8.66 (m, 2H), 8.14 (m, 2H), 7.95 (m, 1H), 6.41 (d, 2H), 4.31 (m, 1H), 3.43 (m, 1H), 
2.83 (s, 1H), 2.78 (m, 1H), 2.10 (m, 2H), 1.57-1.29 (m, 4H), 1.34 (m,2H). 
 
RESULTS 
The products synthesized were characterized via proton NMR; the final spectra 
for compounds C12e, C14e, C16e, C14y, Tz-B and Tz-F are presented in Figures 7 -12. 
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Figure 7: The proton NMR spectrum of dodec-11-enoic acid (2).  
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Figure 8: The proton NMR spectrum of tetradec-13-enoic acid (8). 
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                           Figure 9: The proton NMR spectra of hexadec-15-enoic acid (14). 
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Figure 10: The proton NMR spectra of tetradec-13-ynoic acid (18). 
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Figure 11: The proton NMR spectra of the Tetrazine- biotin conjugate probe (Tz-B) (32).   
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                           Figure 12: The proton NMR spectrum of the Tetrazine-fluorescein probe (Tz-F) (33).
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THE INVERSE ELECTRON DEMAND DIELS ALDER REACTION 
 
 
Bioorthogonal reactions for coupling installed chemical handles to 
complementary reporter molecules have become key strategies for the study of cellular 
modifications. However, while a variety of bioorthogonal partners have been identified 
only a few have found wide use in the presence of complex biological milieu. These 
include the Staudinger ligation and [3+2] cycloaddition between azides and alkynes[13].  
In this study we demonstrate the application of the inverse electron demand Diels-Alder 
(iEDDA) reaction as bioorthogonal strategy for identification of fatty acylation. This 
reaction utilizes a terminal alkene and tetrazine as the complementary reaction partners.  
 
REACTION MECHANISM 
In contrast to the prototypical Diels Alder reaction where an electron rich diene 
reacts with an electron poor dienophile, in an iEDDA reaction an electron rich 
dienophile reacts with an electron poor diene [27]. The first and rate-determining step in 
the reaction mechanism is the [4+2] cycloaddition between the diene (Tz) and alkene 
dienophile to give a bicyclic adduct (b). This is rapidly converted, in a retro-Diels Alder 
step, with the production of dinitrogen to the corresponding 4, 5-dihydropyridazine (c), 
subsequent isomerization leads to the stable 1, 4-dihydro-isomer (d), while oxidation 
yields the pyridazine (e)[28].  
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Figure 13: The iEDDA reaction between the terminal-olefin fatty acid reporter and the tetrazine capture probe. R1 and R2 represent the aromatic substituents of the tetrazine probe while R4 represents the (CH2)nCOOH of the fatty acid mimic.    
REACTION KINETICS 
The iEDDA reaction kinetics is governed by the separation of the HOMO dienophile 
and LUMO diene, which allows for tuning of the reaction kinetics by varying the selection 
of appropriate reaction partners [28]. According to frontier orbital theory, as a general rule 
of thumb, electron withdrawing substituents at the 3- or 6- positions of the tetrazine 
lower the LUMO diene, leading to stronger interactions with the dienophile. This 
promotes the crucial out of plane distortion needed to achieve the transition structure 
with the alkene partner and so results in an increase in the reaction rate [29].   
In the case of 35a, the absence of a strongly electron withdrawing substituent on 
the tetrazine or strongly electron donating substituent on the terminal alkene dienophile 
would suggest an unfavorable reaction. However, Lee et.al. demonstrated the 
favorability of this reaction in a biological system and determined the rate constant for 
the reaction, of 35a and 34a, 0.016 M-1s-1. In order to assess the suitability of Tz-F for 
biological application the reaction kinetics of this tetrazine with 6-16 carbon containing 
terminal alkene acids was evaluated.   
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The reaction kinetics was monitored under pseudo first order conditions with the 
dienophile (F) concentration at least 400 times greater than the diene (T) yielding a 
pseudo first order rate equation- 
 ܴܽݐ݁ = ݇′ [ܶ]         (22) 
the integrated rate equation- 
 ln[ܶ]௧ =  −݇ᇱݐ + ln[ܶ]଴       (23) 
With the second order rate constant given by- 
݇ = ݇′ [ܨ]         (24) 
  
MATERIALS AND METHODS 
 
General information 
Phosphate buffered saline dry powder (PBS), Dimethyl sulfoxide (DMSO), Hex-
5-enoic acid (C6e), Oct-7-enoic acid (C8e) and Dec-9-enoic acid (C10e) were purchased 
from Sigma Aldrich. Dodec-11-enoic acid (C12e), Tetradec-13-enoic acid (C14e), 
Hexadec-15-enoic acid (C16e) were synthesized in lab. Stock solutions (1 M, 0.5 M, and 
0.1 M) of the fatty alkenyl acids (C6e-C16e) were prepared in DMSO. PBS was 
prepared in 1 liter of micro purified water to yield a 0.1 M phosphate buffer solution 
(0.138 M NaCl, 0.0027 M KCl), pH 7.4 at room temperature. Stock solutions (20 mM, 
0.5 mM, 0.2 mM) of the tetrazine probe Tz-F were prepared in DMSO.   
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Experimental procedure 
Kinetic analysis of the iEDDA reaction between Tz-F and the terminal alkenyl 
fatty acids was performed using a Biotek Synergy H1 hybrid multimode micro-plate 
reader (Biotek, VT, USA). The terminal alkenyl fatty acids (C6e-C16e) were prepared in 
a 50% phosphate buffered saline (PBS): 50% DMSO solution at the desired 
concentration (2 mM – 20 mM) in individual eppendorf tubes. The Tz-F (5 µM) was 
added via micropipette and the tubes were vortexed for 30 s before being transferred to a 
96 well plate. The reaction progress was monitored by the fluorescence increase at 521 
nm until saturation was reached, typically 3-4 hours at 37oC, with an excitation of 493 
nm.  The fluorescence data versus time was fitted to a single exponential increase 
equation: y = m1-m2*exp (-m3*m0); using the KaleidaGraph software program such 
that the apparent pseudo first order reaction rate constant (k’) was given by the value of 
m3. The second order rate constant (k) was then calculated using; ݇ = ݇ᇱ[ܨ] for each 
terminal alkene fatty acid-tetrazine cyclo-addition reaction (Table 1). 
  
RESULTS  
In initial kinetic experiments it was observed that as the concentration of alkenyl 
fatty acid increased > 5mM, the anticipated fluorescence increase was observed only 
briefly followed by significant fluorescence quenching. This behavior was noted to be 
observed more drastically with the longer C16e fatty acid (Figure 5). 
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Figure 14: Shows a comparison of the fluorescence observed during the reaction of C6e and C16e (2.5 mM and 20 mM) and TzF (5 M). Note the decrease in fluorescence observed with the reaction of Tz-F and the fatty acid C16e at a high concentration (20 mM).  
This anomalous behavior is likely as a result of micelle formation during the 
reaction and may be compensated for by providing continuous mixing for the duration of 
the kinetic data acquisition. With the current experimental design using the Biotek 
micro-plate reader continuous mixing was not possible, as a result the observed pseudo 
first order rate constants were determined using concentrations between 2-3 mM alkenyl 
fatty acid (C6e-C16e) and 5µM Tz-F ( Figure 6-8).  
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Figure 15: Shows the fluorescence increase observed for the reaction of C6e, C8e, C12e, C14e and C16e fatty acid mimics (2 mM) and Tz-F (5 M).   
 
Figure 16: Shows the fluorescence increase observed for the reaction of C6e, C8e, C12e, C14e and C16e fatty acid mimics (2.5 mM) and Tz-F (5 M).   
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Figure 17: Shows the fluorescence increase observed for the reaction of C6e, C8e, C12e, C14e and C16e fatty acid mimics (3 mM) and Tz-F (5 M).   
Using data collected with C6e-C16e alkenyl fatty acids at 2-3M concentrations 
a second order rate constant (k) was calculated (Table 1). Comparing the second order 
rate constant (kC6e) of 0.058 M-1s-1 to that reported by Lee et. al. for hexenol of 0.036 M-
1s-1  suggests that the methodology used for determination of the reaction rate constant 
needs to be further improved. One strategy which could be used mimics that used 
previously by Lee et. al. using continuous mixing during the course of data acquisition 
and so may eliminate complications of micelle formation with long chain fatty acid 
substrates during the reaction. 
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Table 1: Summarizes the observed reaction rate constant (k’) as well as the second order rate constants (k) for the reaction of C6e-C16e with Tz-F.  
Fatty Acid k’  (x 10-4) s-1 k  M-1s-1 
C6e 2.79 ± 0.059 0.48 ± 0.3 
C8e 2.79 ± 0.061 0.49 ± 0.2 
C10e 2.75 ± 0.064 0.56 ± 0.3 
C12e 3.35 ± 0.139 0.62 ± 1.1 
C14e 3.31 ± 0.152 0.67 ± 0.6 
C16e 2.99 ± 0.105 0.51 ± 0.6 
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 PRE-TARGETING AND LABELING EUKARYOTIC FATTY ACYLATION  
 
 
METABOLIC LABELING OF THE EUKARYOTIC PROTEOME 
Small molecules have shown to have notably better access to intracellular 
compartments, due to their small size [9],[30],[16]. This facilitates the installation of specific 
chemical epitopes onto cellular organelles by exploiting the endogenous synthesis 
machinery of the cell. In this metabolic labeling strategy, the terminal alkene fatty acids 
are introduced into the cell culture medium and taken into the cells via metabolism. The 
terminal alkene fatty acids may be used as a source of energy for the cells or become 
incorporated into cellular organelles. This provides a simplified strategy for 
identification of the fatty acyl modified proteins. 
 
BIOORTHOGONAL LABELING VIA iEDDA 
The installed un-natural functional group, the terminal alkene, can be targeted via 
ligation of a suitable complementary probe. In this instance, a biaryl tetrazine served as 
the complementary probe and ligation was achieved via the inverse electron demand 
Diels alder reaction with the terminal alkene functional group. The terminal alkene fatty 
acids which became incorporated during cell culture then serves as a target for the 
ligation of the complementary tetrazine reporter molecules [31], [32].  In this study the 
reactive biaryl tetrazine is conjugated to a fluorescent moiety (Tz-F), which facilitates 
the rapid visualization of the installed fatty acylated proteins by in gel fluorescence 
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imaging. In addition the biaryl tetrazine conjugated to biotin (Tz-B) was used to 
visualize as well as facilitate the enrichment of fatty acylated proteins for proteomic 
identification.  
 
MATERIALS AND METHODS 
 
General information 
Fetal Bovine Serum (FBS), Dulbecco Modified Eagle Medium (DMEM), 
Phosphate Buffered Saline dry powder (PBS), Protease inhibitor cocktail, Dimethyl 
sulfoxide (DMSO), Trypsin, Hex-5-enoic acid (C6e), Oct-7-enoic acid (C8e) and Dec-9-
enoic acid (C10e) were purchased from Sigma Aldrich. Dodec-11-enoic acid (C12e), 
Tetradec-13-enoic acid (C14e), Hexadec-15-enoic acid (C16e) were synthesized in lab. 
Compound KC6e was provided by a lab colleague, Yan Jiun Lee PhD, while compound 
AS1-126-1 was provided by Dr. Frederic Taran from the French Alternative Energies 
and Atomic Energy Commission (CEA), France.  
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 Figure 18: The structure of compound KC6e, used for the expression of sfGFP containing 6-carbon terminal alkene modified lysine residues and the chelating azide, AS1-126-1, used in labeling terminal alkyne containing proteins.   
Streptavidin – HRP antibody and Pierce ECL Western Blotting Substrate were 
purchased through Biorad. Stock solutions (20 mM) of the fatty alkenyl acids were 
prepared in DMSO and filtered sequentially through 0.45uM and 0.2uM sterile filters. 
This stock was used to prepare a fatty acid enriched culture media by adding the 
necessary volume to achieve the desired concentration (typically 100 M) to a 10:90 
FBS: DMEM solution, vortexing 3-5 min and allowing the solution to rest for 8-10 mins 
before use.  
Proteins labeled with Tz-F were imaged using a BioRad Molecular Imager 
ChemiDocTM x RS+ following SDS-PAGE. Proteins labeled with Tz-B were transferred 
to PVDF membranes using the BioRAD Trans-Blot Turbo Transfer System. After 
blocking with 5% BSA in PBST overnight at 4oC, rinsing with PBST (10 mins) and 
incubation in the streptavidin-HRP antibody (1:5000) for 4 hours at room temperature 
(or overnight at 4oC). The membrane was rinsed in PBST (10 mins) and labelled proteins 
visualized using PierceTM ECL western blotting substrate. 
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Expression of sfGFP-KC6e 
A previously reported protocol was followed to genetically incorporate KC6e 
into sfGFP. Transformed E. coli BL21 (DE3) cells with pET-PylTsfGFPS2TAG and 
pEVOL-PylT-BuKRS was used to inoculate LB media and grown at 37 °C with 
agitation until the OD600 reached 0.6-0.8. The medium was then supplemented with 5 
mM KC6e, 1 mM IPTG, and 0.2% arabinose, followed by incubation at 37 oC with 
agitation for 8 h for protein expression. 
 After centrifugation, the cell pellet was resuspended in ice cold lysis buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by sonication. The 
lysate was centrifuged (10000 g, 4oC, 1h) and the supernatant was collected and 
subjected to Ni-NTA (Qiagen) affinity chromatography. The supernatant was incubated 
with Ni-NTA resin (1h, 4oC). The slurry was then loaded to a column and the protein-
bound resin was washed with washing buffer (50 mM NaH2PO4, 300 mM NaCl, 45 mM 
imidazole, pH 8.0) followed by eluting the bound protein with elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). The eluted protein was dialyzed 
(10mM ABC) and lyophilized. The lyophilized sfGFP-KC6e was dissolved in PBS and 
concentration determined via UV absorbance at 485 nm. [Extinction coefficient 
8.33x104 M-1 cm-1] 
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Incorporation of C6e-C16e fatty acids into HEK-293T cells 
Passaged HEK-293T cells were seeded on 6 well plates (2-3 x 105 cells/mL) and 
grown in 10:90 FBS: DMEM (2mL) until 70-80% confluence was reached (typically 24-
30 hours). The media was removed via vacuum aspiration and the cells were gently 
washed with PBS (2 mL) before the fatty acid enriched media was replaced and the cells 
grown at 37 oC with 5% CO2 for 24 hours (or duration required by experiment). The 
enriched media was then removed by vacuum aspiration, the cells washed with PBS (2 x 
1mL) and the media replaced with DMEM (2mL). The cells were returned to the 
incubator for an additional 2 hours. Once removed from the incubator the media was 
removed and the cells washed, RIPA lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM 
NaCl, 1 mM Na3VO4, 1 mM NaF, 1% Np40, protease inhibitor cocktail) was added and 
the cells were kept on ice for 10 mins before being scraped and collected. The cells were 
further lysed by 5 rounds of freeze-thaw with 30 s intervals of votexing after each thaw. 
The cell debris was pelleted by centrifugation 14000 rpm for 30 mins and the 
supernatant collected. Cell lysate protein concentration was determined using PierceTM 
BCA Assay and aliquoted (100 ug protein).  
  Incorporation of C6y-C14y fatty acids into HEK-293T cells 
Stock solutions (20 mM) of the fatty alkynl acids (C6y and C14y) were prepared 
in DMSO and filtered through 0.45 uM sterile filter followed by 0.2 uM sterile filter. 
This stock was used to prepare a fatty acid enriched culture media containing C6y (100 
M) or C14y (100 M) in 10:90 FBS: DMEM solution. The enriched media was 
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vortexed 3-5 mins and allowed to rest for 8-10 mins. HEK 293T cells cultured in the 
presence of the alkynl fatty acids for 24 hours before being washed and lysed as 
described earlier. 
 
Tetrazine labeling of sfGFP-KC6e purified proteins 
The purified protein samples sfGFP-KC6e and sfGFP-wt (25 ug) were labeled 
with Tz-F (0.25 M) or Tz-B (0.25 mM) in PBS buffer at pH 7.4 were incubated at 37 
oC for 4 hours. The labelled proteins were precipitated using 10% TCA, washing with 
acetone to remove excess of the tetrazine probe prior to electrophoresis. The precipitated 
proteins were re-dissolved in PBS supplemented with 2% SDS and non-reducing sample 
loading buffer. The sample was fully denatured by heated to 100oC for 5 mins before 
being loaded to a 4-12% acrylamide gel for electrophoresis. Tz-F labeled proteins were 
visualized via in gel fluorescence and Tz-B labeled proteins were visualized by western 
blot. (Figure 10) 
 
Tetrazine labeling of cell lysates 
Cell lysates (100ug) labelled with Tz-F or Tz-B (0.25mM) in PBS buffer for 4 
hours at 37oC. The labelled proteins was precipitated using 10% TCA, washing with 
acetone to remove excess tetrazine probe. The precipitated proteins were re-dissolved in 
PBS with 2% SDS. Non-reducing sample loading buffer was added and the sample was 
fully denatured by heated to 100oC for 5 mins sample before being loaded to a 4-12% 
acrylamide gel for electrophoresis. Proteins labeled with Tz-F was observed via in gel 
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fluorescence while those labeled with Tz-B was observed via western blot. (Figure 11-
14)  
 
 Copper asisted azide-alkyne labelling of cell lysates 
Stock solutions of the chelating azide - AS1-126-1 (2.5 mM), CuSO4 (2.5 mM) 
and Sodium ascorbate (125 mM) was prepared in milliQ purified water. The chelating 
azide (100 M) and CuSO4 (100 M) were allowed to complex for 1 hour at room 
temperature. Sodium ascorbate (5 mM) was added and the solution was vortexed and 
allowed to stand another 10 mins before use. Cell lysates (100 ug) in PBS buffer was 
added to the CuAAC reagent mixture, vortexed and maintained at for 37 oC for 4 hours 
for labelling. The labelled proteins was precipitated using 10% TCA, washing with 
acetone to remove excess tetrazine probe. The precipitated proteins were re-dissolved in 
PBS with 2% SDS. Non-reducing sample loading buffer was added and the sample was 
fully denatured by heated to 100oC for 5 mins sample before being loaded to a 4-12% 
acrylamide gel for electrophoresis. Labelled proteins were observed via western blotting. 
(Figure 15)  
 
HEK 293T cell fractionation 
Cells cultured were cultured as described earlier in media enriched with C14e and 
C16e were fractionated as described by Holden et.al.[33] Enriched media was removed and 
the cells were washed with PBS (1 x 1 mL/well), the cells were gently dislodged using ice 
cold PBS (1 mL/well) and pipetted into an Eppendorf tube. The cell suspension was 
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centrifuged 100 x g for 10 mins at 4oC to pellet the cells. The supernatant was removed 
and the cell pellet was resuspended by gentle pipetted in 400 uL Buffer 1 (150 mM NaCl, 
50 mM HEPES, pH 7.4, 25 g/mL digitonin and protease inhibitor cocktail). The cells 
were incubated for 10 mins end over end at 4oC, then centrifuged at 2000 x g for 10 mins 
and the supernatant containing the cytosol enriched fraction was collected. 
 The pellet was resuspended in 400 uL Buffer 2 (150 mM NaCl, 50 mM HEPES 
pH 7.4 and 1% Np40) and incubated on ice for 30 mins. The cell suspension was then 
centrifuged 7000 x g for 10 mins. The supernatant containing the membrane bound 
organelles was collected. The pellet was again resuspended in 400 uL Buffer 3 (150 mM 
NaCl, 50 mM HEPES pH 7.4, 0.5% Sodium deoxycholate, 0.1% Sodium dodecyl sulfate 
and 1U/mL Benzonase). The cells were incubated overnight end over end at 4oC 
followed by centrifugation 7000 x g for 10 mins. The supernatant containing the nuclear 
membranes and nuclear proteins were collected. To the remaining pellet was added 200 
L Buffer 4 (150 mM NaCl, 50 mM HEPES pH 7.4, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulfate and 100 mM dithiothretol), vortexed for 30 seconds and boiled. 
The sample was pelleted by centrifugation at 10000 x g for 10 mins. Protein 
concentration was determined for supernatant samples collected from buffers 1, 2 and 3 
using the PierceTM BCA Protein Assay Kit. Due to interference from the concentration 
of DTT used in buffer 4 the protein concentration was not calculated. The collected 
supernatant samples (100 g protein) were labelled using Tz-F (0.25M) for 4 hours, 
precipitated using 10% TCA, washed with acetone, resuspended in sample loading 
buffer and examined by SDS-PAGE on a 4-12% gel. (Figure 16) 
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RESULTS 
Expressed and purified sfGFP with a C6e modification was labelled with Tz-F or 
Tz-B to verify the functionality of the terminal alkene-tetrazine labeling system (Figure 
10), as illustrated the terminal alkene containing sfGFP-KC6e was labelled exclusively 
confirming the selectivity and specificity of this reaction. 
 
Figure 19: sfGFP-WT and sfGFP-KC6e (25 ug) were labeled with 0.25 mM Tet-F and Tet-B for 6 hrs at 37oC and visualized via in gel fluorescence and western blot analysis respectively.   
An initial test of the metabolic labeling conditions using fatty acid enriched 
media with C6e (100 M) or C14e (100 M) incubating for 24 hours followed by cell 
lysis and labeling of whole cell lysates with Tz-F or Tz-B indicated the presence of fatty 
acylated proteins [30]. (Figure 20) 
  
 50 
 
 
Figure 20: In gel fluorescence and chemiluminescent western blot of HEK 293T cell lysate from cells cultured in the presence of C6e or C14e (100 M) and labelled with Tz-F ( 0.1 mM, 0.25 mM)  or Tz-B ( 0.1 mM, 0.25 mM) for 4 hours. For western blots the proteins were transferred to PVDF membranes, blocked with 5% BSA, incubated in Streptavidin-HRP and visualized.  
In order to identify the best conditions for achieving optimal metabolic labeling, 
various concentrations of the different terminal alkene fatty acids were provided in the 
growth medium of HEK-293T cells. Using both the level of labelled proteins observed 
via western blot as well as the appearance of the cultured cells it was determined that 
100 uM of fatty acid was sufficient to gain the best results. While higher concentrations 
appeared to give increased incorporation of terminal alkene the level of cell confluence 
reached following 24 hours of culture suggested that higher concentrations also resulted 
in increased cellular stress leading to decreased growth.  
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Figure 21: Chemiluminescence observed via western blotting of cell lysates cultured in varying concentrations of C14e enriched media to determine the optimum concentration for metabolic labeling. The cell lysates were labelled with Tz-B (0.25 mM) for 4 hours, transferred to PVDF membranes, blocked with 5% BSA, incubated in Streptavidin-HRP and visualized.  
Metabolic labelling conditions were further optimized by determining the best 
duration for culturing cells in the fatty acid enriched media. An enriched media 
containing C14e (100 M) was prepared and cells were grown for 6, 12, 18, 24, 36 and 
48 hours. The enriched media was replaced after 24 hours to ensure that the growth 
media was not toxic. The control sample was cultured for 36 hours in 10:90 FBS/DMEM 
with DMSO. (Figure 22) 
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Figure 22: Chemiluminescence observed via western blotting of cell lysates; cells were cultured in C14e (100 M) enriched media for varying durations 6, 12, 18, 24 and 36 hours. The cell lysates were labeled with Tz-B (0.25 mM) for 4 hours, transferred to PVDF membranes, blocked with 5% BSA, incubated in Streptavidin-HRP and visualized.   
Cells were also cultured for 24 hours in media enriched with fatty acids of 
varying chain lengths C6e, C8e, C10e, C12e, C14e, and C16e. A control sample was 
cultured for 24 hours in 10:90 FBS/DMEM with DMSO. The results suggest that there is 
a preference for incorporation of longer chained fatty acid substrates by the increased 
labeling observed in the C14e-C16e lysates. This result was anticipated as myristoyl and 
palmitoyl fatty acid modifications are widely identified modifications in the eukaryotic 
proteome. (Figure 23) 
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Figure 23: Chemiluminescent visualization of modified cell lysates cultured in enriched media with 100 M C6e- C16e for 24 hrs. The collected cell lysates were labelled with Tz-B (0.25 mM) for 4 hours , transferred to PVDF membranes, blocked with 5% BSA, incubated in Streptavidin-HRP.  
To investigate the difference in fatty acylation targets between a terminal alkene 
fatty acid (C6e, C14e) and terminal alkyne fatty acid (C6y, C14y) HEK cells were 
cultured in media supplemented with the respective fatty acid (100 M) for 24 hours. 
The cell lysates were labelled using either Tz-B (0.1 mM) or a chelating biotin azide 
AS1-126-1 (0.1 mM) for 4 hours. The results though preliminary indicate that the 
terminal alkyne fatty acid modifies different proteins than the terminal alkene fatty acid. 
Also the terminal alkyne fatty acid has a broader range of targets than the terminal 
alkene which may account for the number of falsely identified fatty acid modification 
sites. (Figure 24) 
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Figure 24: Chemiluminescent visualization of cell lysates obtained from cells cultured in enriched media with 100 M C6e, C6y, C14e or C14y for 24 hrs. The collected cell lysates from C6e and C14e treatments were labelled with Tz-B (0.1 mM) for 4 hours. The cell lysates treated with C6y and C14y were labelled with AS1-126-1 (0.1 mM), CuSO4 (0.1 mM) and sodium ascorbate (5 mM) for 4 hours. The modified proteins were then transferred to PVDF membranes, probed with Strep-HRP and visualized.  
One strategy which was attempted to deconvolute the complex mixture of 
proteins obtained following cell lysis uses cellular fractionation. (Figure 25) By 
methodically separating the cell lysates into its cytosolic proteins (B1), proteins 
contained in the cells membranous organelles (B2) including the endoplasmic reticulum, 
golgi, mitochondria and nuclear luminal proteins as well as those in the nucleus and 
nuclear membrane (B3) and insoluble proteins (B4) it would be possible to evaluate the 
localization of the fatty acyl modifications as well as reduce the sample complexity.  
This process would be very advantageous for mass spectroscopy analysis which 
often suffers due to the difficulties associated with deconvolution of samples prior to 
ionization.  In our experiments, the results indicate that fatty acyl modifications are 
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focused mainly on membranous cellular organelles. This aligns with findings which 
have identified fatty acyl modifications on cell membranes and other hydrophobic 
proteins[34], [7].   
 
 
 
 
 
        
 
 
 
Figure 25: In gel fluorescence of cell lysates obtained from cells cultured in enriched media with 100 M C14e or C16e for 24 hrs. The cell lysates were collected and labelled with Tz-F (0.25 mM) for 4 hours and the modified proteins visualized by in gel fluorescence.  
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CONCLUSIONS AND FUTURE PERSPECTIVES  
 
In using a tetrazine- terminal olefin methodology we have demonstrated that a 
terminal alkene fatty acid mimic can be incorporated successfully into the eukaryotic 
proteome. Using the tetrazine fluorescein and biotin conjugated probes we have 
selectively labelled fatty acid modified cellular components. Evidence has also been 
obtained to show that fatty acyl modifications are mainly localized on the cells 
membranous organelles including the endoplasmic reticulum, golgi, mitochondria and 
nuclear luminal proteins.  
A comparison of the labelling of similar terminal alkene and alkyne fatty acid 
surrogates provides insufficient results to suggest that the iEDDA strategy is more 
efficient or effective than CuAAC in identifying fatty acid modifications. However, with 
further work this alternative labeling strategy may be advantageous in validating some of 
the catalogued sites of fatty acyl modifications. This tetrazine-alkene system would 
provide another unique data set which may potentially be more representative of 
endogenous processes than those currently being used. Furthermore, the simplicity of 
this chemical strategy makes it readily adapted to fit other research objectives offering 
another novel research tool to the extended scientific community.  
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APPENDIX SUPPLEMENTARY FIGURES 
  
 
Figure S1: The proton NMR spectra of compound 4. 
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Figure S2:  The proton NMR spectra of compound 5. 
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Figure S3: The proton NMR spectra of compound 6.  
11O O 
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Figure S4: The proton NMR spectra of compound 7. 
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Figure S5: The proton NMR spectra of compound 10. 
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Figure S6: The proton NMR spectra of compound 11. 
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Figure S7: The proton NMR spectra of compound 13. 
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Figure S8: The proton NMR spectra of compound 16. 
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Figure S9: The proton NMR spectra of compound 17. 
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Figure S10: The proton NMR spectra of compound 20. 
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Figure S11: The proton NMR spectra of compound 25. 
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Figure S12: The proton NMR spectra of compound 26. 
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Figure S13: The proton NMR spectra of compound 28. 
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Figure S14: The proton NMR spectra of compound 31. 
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